Catalog No.
Product Name
Application
Product Information
Citations
-
Antioxidant Agent
Crocetin monomethyl ester serves as an antioxidant agent, derived from Crocus sativus. It exhibits significant anti-inflammatory and neuroprotective properties, making it valuable in neurological research. This compound promotes the clearance of amyloid-β by inducing autophagy through the STK11/LKB1-mediated AMPK pathway, highlighting its potential application in Alzheimer’s disease studies and related neurodegenerative disorders. -
Amyloid-Beta and Tau Inhibitor
Aβ/tau aggregation-IN-1 is a selective inhibitor of amyloid-beta (Aβ1-42) β-sheet formation and tau protein aggregation. With KD values of 160 μM for Aβ1-42 and 337 μM for tau, this compound demonstrates significant potential in research related to neurodegenerative disorders such as Alzheimer's disease. Its ability to cross the blood-brain barrier further supports its use in studies aimed at understanding the pathophysiology of amyloid and tau accumulation in the central nervous system. -
Aβ/tau Protein Aggregation Inhibitor
DN5355 is a small molecule inhibitor of amyloid β protein (Aβ) and hyperphosphorylated tau protein aggregation. It effectively inhibits the formation of Aβ and tau fibrils while also promoting the disaggregation of pre-formed aggregates. This compound is valuable for research applications focused on Alzheimer's disease and the underlying mechanisms of protein aggregation associated with neurodegeneration. -
Aβ40 Aggregation Inhibitor
Biphenyl-3′,3,4,4′-tetrol (BPT) is a potent inhibitor of Aβ40 aggregation, targeting the aggregation process associated with amyloid-beta peptides. This compound is relevant for research into neurodegenerative diseases, particularly Alzheimer's disease, by facilitating studies aimed at understanding and potentially mitigating the pathological effects of amyloid plaque formation. -
Amyloid-β Inhibitor
Semilicoisoflavone B is an isoflavone derived from Glycyrrhiza uralensis Fisch, functioning primarily as an inhibitor of amyloid-β (Aβ) secretion. It reduces Aβ levels by inhibiting the expression and activity of β-secretase-1 (BACE1). This compound enhances PPARγ expression while simultaneously inhibiting STAT3 phosphorylation, leading to decreased BACE1 levels. Semilicoisoflavone B is relevant for research into Alzheimer's disease and mechanisms of neurodegeneration. -
RAGE Ligand
MG-H1 is a ligand for the receptor for advanced glycation end products (RAGE), exhibiting a binding affinity (Kd) of 4.12 nM. It interacts specifically with human umbilical vein endothelial cells, making it a valuable tool for studying endothelial dysfunction. MG-H1 is particularly relevant in the context of diabetes research, where it aids in understanding the mechanisms of vascular complications associated with the disease. -
Aβ Inhibitor
Aβ aggregation-IN-1 is a selective inhibitor of amyloid-beta aggregation, effectively targeting the fibrillogenesis process. It demonstrates significant biological activity with IC50 values of 3.92 µM for aggregation and 7.19 µM for disaggregation. Additionally, Aβ aggregation-IN-1 inhibits malondialdehyde formation, enhances intracellular reduced glutathione levels, and reduces caspase 3 activity in neuronal cells. This compound is valuable for research in Alzheimer's disease and related neurodegenerative disorders. -
Amyloid β
β-Amyloid (1-37) (human) is a peptide derived from amyloid precursor protein, primarily targeting amyloid β. This biomarker is associated with cognitive decline and demonstrates a moderate correlation with Mini-Mental State Examination (MMSE) scores in Alzheimer's disease. β-Amyloid (1-37) serves as a valuable tool in research applications focused on Alzheimer's disease diagnosis and progression. -
Anti-amyloid Drug
Aβ/tau aggregation-IN-3 is a potent inhibitor of amyloid protein aggregation, demonstrating an IC50 of 0.85 μM in the Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. This compound exhibits significant anti-amyloid activity, making it a valuable tool for research into Alzheimer’s disease and other amyloid-related disorders. Its mechanism of action positions it as a promising candidate for investigations focused on therapeutic strategies aimed at reducing amyloid plaque formation. -
AChE Inhibitor
Buntanetap L-Tartrate is a selective acetylcholinesterase (AChE) inhibitor with an IC50 of 22.2 nM. This compound functions as a neurotoxic protein translation inhibitor, targeting proteins such as amyloid precursor protein (APP), α-synuclein (αSYN), and huntingtin protein (HTT). By obstructing the mRNA translation of β-amyloid precursor protein, Buntanetap reduces its production and exhibits anti-inflammatory properties. Its applications include research related to Alzheimer's disease and Parkinson's disease. -
β-Amyloid
β-Amyloid (22-35) is a fragment comprising residues 22-35 of the β-amyloid protein. This compound exhibits cytotoxic effects on cultured rat hippocampal neurons in serum-free conditions. Additionally, β-Amyloid (22-35) has the capability to form aggregates and amyloid fibrils similar to those produced by full-length β-amyloid protein in neutral buffer solutions, making it a valuable tool for studying Alzheimer's disease pathology and neurodegeneration processes. -
Aβ42 Ligand
Aβ42 agonist-2 is a small molecule compound designed to target Aβ42 ligands. It facilitates the aggregation of Aβ42 by promoting the self-assembly of nontoxic aggregates and accelerating fibril formation through interactions with Aβ42 oligomers and pentamers. Additionally, Aβ42 agonist-2 has been shown to mitigate Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells, making it a valuable tool for investigating Alzheimer’s disease pathology and potential therapeutic strategies. -
Amyloid-β
β-Amyloid (1-20) is a peptide comprising the first 20 amino acids of the beta amyloid protein. This compound is primarily associated with the study of Alzheimer's disease and plays a crucial role in the formation of amyloid plaques. It is utilized in research applications investigating neurodegenerative processes, peptide aggregation, and the mechanisms underlying cognitive decline. -
Pyr Precursor
Amyloid β-Protein (3-42) is a precursor of pyroglutamate-modified Aβ, playing a critical role in the formation of amyloid plaques associated with Alzheimer's disease. This peptide contributes to the aggregation of Aβ(1-42), and its modified form, pEAβ(3-42), is known to accelerate Aβ(1-42) aggregation while inhibiting its nucleation processes. Research applications include studies on amyloid pathology and the mechanisms underlying Alzheimer's disease. -
β-Amyloid Inhibitor
RI-OR2-TAT is a potent inhibitor of β-Amyloid oligomerization, enhanced by the incorporation of the HIV protein transduction domain TAT. This compound exhibits a binding affinity to Aβ42 fibrils with a Kd value ranging from 58 to 125 nM. RI-OR2-TAT effectively reduces Aβ aggregation and plaque formation, mitigates microglial activation and oxidative stress, and promotes neurogenesis by increasing the proliferation of young neurons in the dentate gyrus. It is a valuable tool for research focused on neurodegenerative diseases, particularly Alzheimer's disease. -
Amyloid-beta 42 Binder
4-Sulfocalix[4]arene is an amyloid-beta 42 binder that exhibits a dissociation constant (Kd) of 5.39 µM, indicating a strong affinity for binding to this protein. Its ability to inhibit amyloid β-peptide fibrillation makes it a valuable tool in research focused on Alzheimer's disease pathology. Additionally, 4-Sulfocalix[4]arene can reduce the cytotoxicity associated with amyloid aggregates, providing insights for therapeutic strategies targeting amyloid-related neurodegeneration. -
Aβ Probe
MCAAD-3 is a near-infrared imaging probe designed to target amyloid-beta (Aβ) species, facilitating visualization of Aβ plaques in vivo. It possesses exceptional affinity for Aβ polymers, with a dissociation constant (Ki) exceeding 106 nM. This probe effectively permeates the blood-brain barrier, making it a valuable tool for studying Alzheimer’s disease and related neurodegenerative conditions in transgenic mouse models. -
Anti-Amyloid Agent
Anti-amyloid agent-1 is a potent anti-amyloid compound that effectively inhibits amyloid aggregation. This agent serves as a valuable tool for investigating amyloidosis and understanding its molecular mechanisms. Its application in research can aid in the development of therapeutic strategies for diseases associated with amyloid formation. -
Ecdysterones
2-O-Acetyl-20-hydroxyecdysone is an ecdysteroid that targets various biological pathways associated with insect and plant physiology. This compound has demonstrated efficacy in inhibiting amyloid-β42 (Aβ42)-induced cytotoxicity, potentially reducing the formation of neurotoxic Aβ oligomers by promoting their transformation into less harmful fibrils. Its biological activity suggests applications in research related to neurodegenerative diseases and the modulation of protein misfolding. -
Neuroprotective Agent
(-)-Clausenamide is a neuroprotective agent isolated from the leaves of Clausena lansium (Lour.) Skeels that enhances cognitive function under both normal and pathological conditions. It effectively inhibits β-amyloid (Aβ) toxicity and prevents neurofibrillary tangle formation by blocking tau protein phosphorylation. Additionally, (-)Clausenamide demonstrates significant neuroprotective activity against the Aβ25-35 peptide. This compound is valuable for research applications related to Alzheimer's disease (AD).
-
Luminescent Conjugated Oligothiophene Probe
h-FTAA is a luminescent conjugated oligothiophene (LCO) probe that selectively targets amyloid protein aggregates, including Aβ plaques. This compound enables the differentiation of various aggregate conformations through fluorescence signal changes. Additionally, h-FTAA has been shown to reduce the neurotoxicity of Aβ1-42 and the Arctic mutant Aβ (AβArc), providing protection to SH-SY5Y neuroblastoma cells. Its application includes the dynamic tracking of Aβ plaque formation and maturation processes, making it valuable for research in neurodegenerative diseases. -
Aβ42 Ligand
Aβ42 agonist-1 is a selective ligand targeting Aβ42, facilitating the aggregation of Aβ42 peptides. This compound interacts with Aβ42 oligomers and pentamers, promoting the self-assembly of nontoxic aggregates and accelerating the formation of fibrils. Additionally, Aβ42 agonist-1 effectively inhibits Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells, making it a valuable tool for research into Alzheimer's disease mechanisms and therapeutic strategies. -
Aβ1-40 Aggregation Inhibitor
QR-0217 is a potent inhibitor of Aβ1-40 aggregation, exhibiting an IC50 value of 7.5 µM. This compound also demonstrates the ability to inhibit α-synuclein aggregation, making it useful in studies related to neurodegenerative diseases. Additionally, QR-0217 has been shown to mitigate memory impairments associated with Aβ neurotoxicity, providing a valuable tool for research on Alzheimer's disease and related conditions. -
Antiepileptic Agent
Otophylloside B is a C-21 steroidal glycoside with significant antiepileptic properties. It is isolated from Qingyangshen and demonstrates protective effects against Aβ toxicity, primarily by reducing Aβ deposition through decreased expression of its mRNA. This compound is valuable for research into neuroprotective strategies and the management of epilepsy. -
Amyloid-β
BTA-1 is an uncharged derivative of thioflavin-T designed to target amyloid-β (Aβ) fibrils. It exhibits a high affinity for Aβ aggregates, facilitating effective binding and visualization in amyloid research. BTA-1 demonstrates excellent brain penetration and clearance, making it a valuable reagent for studies related to neurodegenerative diseases, such as Alzheimer's disease. -
β-amyloid Aggregation Inhibitor
Methyl tridecanoate is a β-amyloid aggregation inhibitor that demonstrates a moderate capacity to impede the formation of β-amyloid fibrils, which are implicated in neurodegenerative diseases such as Alzheimer's. Additionally, this compound displays weak inhibition of acetylcholinesterase (AChE), an enzyme involved in cholinergic neurotransmission. Its dual activity suggests potential applications in research focused on Alzheimer's pathology and related cognitive disorders. -
Amyloid-beta precursor protein (APP) synthesis reducer
Mivelsiran is a small interfering RNA (siRNA) that specifically reduces the synthesis of amyloid-beta precursor protein (APP). This compound is primarily utilized in research focusing on Alzheimer's disease, providing insights into the mechanisms of amyloid plaque formation and the associated neurodegenerative processes. Mivelsiran serves as a valuable tool for exploring therapeutic strategies aimed at mitigating APP-related pathologies. -
Amyloid-β Inhibitor
2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 is a deuterated derivative of 2-Hydroxy-5-(phenyldiazenyl)benzoic acid that primarily targets amyloid-β. This compound exhibits significant inhibitory activity against amyloid-β aggregation, making it valuable for research related to Alzheimer's disease and other neurodegenerative disorders. It serves as a useful tool for investigating the mechanisms of amyloid pathology and potential therapeutic strategies. -
Antioxidant Agent
Antioxidant Agent-2 is a potent antioxidant and selective metal ion chelator that effectively penetrates the blood-brain barrier. This compound exhibits significant neuroprotective and hepatoprotective effects, making it a valuable tool in the research of Alzheimer's disease and related neurodegenerative disorders. Its ability to mitigate oxidative stress and metal-induced toxicity highlights its potential for therapeutic applications in neurological health. -
LC Kinetic Stabilizer
LC Kinetic Stabilizer-2 is a potent agent designed to stabilize amyloidogenic immunoglobulin light chains (LC) by enhancing their kinetic stability, with an EC50 of 24 nM. This compound is particularly useful in research applications focused on protein misfolding diseases, amyloidosis, and related pathologies. It enables the investigation of LC dynamics and potential therapeutic interventions to prevent aggregation in affected tissues. -
Aβ1-40 Aggregation Activator
Glycerophosphorylethanolamine sodium is an active phosphodiester metabolite of phosphatidylethanolamine that functions as an Aβ1-40 aggregation activator. This compound promotes the aggregation of amyloid β-protein (Aβ1-40) in vitro, facilitating studies related to amyloid plaque formation. Glycerophosphorylethanolamine sodium is particularly relevant for research in neurodegenerative diseases, including Alzheimer’s disease. -
Aβ1–42 Aggregation Inhibitor
Aβ1–42 aggregation inhibitor 2 is a potent inhibitor of Aβ1-42 aggregation, which is significant in the study of Alzheimer's disease. This compound demonstrates strong antioxidant properties, effectively chelates metal ions, and alleviates oxidative stress. Additionally, it exhibits neuroprotective and anti-neuroinflammatory activities, making it a valuable tool for research focused on neurodegenerative disorders and potential therapeutic interventions. -
Amyloid-β Fragment
β-Amyloid (17-40) is a fragment of the Amyloid-β peptide that primarily targets neurotoxic pathways associated with Alzheimer's disease. This compound has demonstrated notable neurotoxic effects in SH-SY5Y and IMR-32 neuronal cell lines. Due to its biological activity, β-Amyloid (17-40) is a valuable tool for investigating the mechanisms underlying neurological diseases and for developing potential therapeutic strategies. -
BACE1 Inhibitor
CTS-21166 is a selective inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), designed to penetrate the blood-brain barrier effectively. It demonstrates the ability to reduce levels of amyloid-beta (Aβ) in the brain, making it a valuable tool for studying the pathogenesis of Alzheimer's disease. CTS-21166 is suitable for use in both in vitro and in vivo research applications focused on Alzheimer's and related neurodegenerative disorders. -
Aβ Fragment
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of the amyloid β-protein (Aβ) with a specific mutation at Glu22 to Gly22. This modification enhances the aggregation tendency of Aβ, a key component in the formation of amyloid plaques associated with Alzheimer's disease. Research applications include studying the molecular mechanisms of amyloid aggregation and evaluating potential therapeutic strategies for Alzheimer's disease. -
Amyloid-β
β-Amyloid (10-35), amide targets amyloid-β, a key player in the pathogenesis of Alzheimer’s disease. Comprising 26 amino acids derived from the 10-35 region of the Aβ peptide, this reagent is critical for studying the aggregation and deposition of amyloid plaques. It is valuable for research applications focused on neurodegeneration, protein misfolding, and Alzheimer's pathology. -
Amyloid-β Inhibitor
YIAD-0205 is an orally bioavailable inhibitor of amyloid-β (Aβ) aggregation, specifically targeting Aβ(1-42). This compound exhibits significant in vivo efficacy in a transgenic mouse model of Alzheimer's disease carrying five familial mutations (5XFAD). Its application lies in Alzheimer's research, particularly in studies exploring therapeutic strategies aimed at mitigating Aβ-related neurodegeneration. -
Aβ Fragment
Amyloid β-Protein (5-42) is an Aβ fragment that plays a critical role in the formation of amyloid plaques, a pathological hallmark of Alzheimer's disease. This peptide exhibits neurotoxic properties and serves as a key research tool in studies investigating the mechanisms underlying amyloid aggregation and neurodegeneration. It is commonly utilized to evaluate potential therapeutic agents aimed at mitigating Alzheimer's disease-related cognitive decline. -
Amyloid β Inhibitor
Aβ-IN-3 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. This compound effectively inhibits the aggregation of Aβ42, making it a valuable tool in the study of amyloid-related pathologies. However, Aβ-IN-3 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it alter the aggregation state of Aβ42 into a non-toxic form. Its primary applications lie in research focused on Alzheimer's disease and amyloid aggregation mechanisms. -
Nicardipine Metabolite
Dehydro nicardipine, a metabolite of Nicardipine, belongs to the dihydropyridine class of compounds. This compound selectively inhibits the aggregation of amyloid-beta (Aβ) monomers and regulates the extension and binding of soluble Aβ aggregates. Additionally, it alters the morphology of Aβ aggregates and inhibits their growth in length. Dehydro nicardipine is valuable for research applications focused on Alzheimer's disease. -
Aβ Inhibitor
PPI-1019 is an amyloid beta (Aβ) inhibitor that specifically targets the aggregation of Aβ peptides. This compound demonstrates potential neuroprotective effects, making it a valuable tool for researching neurodegenerative disorders, particularly Alzheimer's disease. Its role in modulating Aβ-related toxicity makes PPI-1019 significant for studies aimed at understanding the pathophysiology of amyloid plaque formation and developing therapeutic strategies. -
Amyloid-β
β-Amyloid (1-9) is an N-terminal fragment of the amyloid-β peptide that encompasses amino acid residues 1 to 9. This fragment contains a B cell epitope, making it valuable for immunological studies. Although it lacks T cell epitopes, β-Amyloid (1-9) remains capable of forming amyloid fibrils and does not diminish fibril polymorphism when removed from the full-length Alzheimer's amyloid-β peptide (1-40). This specificity makes it useful for research into Alzheimer’s disease and related neurodegenerative conditions. -
Amyloid β-Protein Mutat
(Lys22)-Amyloid β-Protein (1-42) is a modified variant of the wild-type Amyloid β-Protein (1-42) peptide, featuring a lysine substitution at position 22. This mutation enhances the peptide's propensity to interact with molecular targets involved in Alzheimer’s disease pathology. It is essential for studies investigating amyloid aggregation, neurotoxicity, and the design of potential therapeutic agents for neurological disorders. -
Aβ Oligomers Formation Inhibitor
Aβ-IN-6 is an Aβ oligomers formation inhibitor that effectively reduces pro-inflammatory cytokine release from microglia. This compound significantly promotes Nrf2 nuclear translocation, thereby interfering with the aggregation of Aβ oligomers. Aβ-IN-6 offers neuroprotective effects through modulation of redox-sensitive signaling pathways in in vivo oxidative stress models. Its oral bioactivity and combined anti-inflammatory, antioxidant, and anti-oligomeric properties make Aβ-IN-6 a valuable reagent for research into Alzheimer's disease. -
β-Amyloid (1-42) Dutch Mutation
(Gln22)-Amyloid β-Protein (1-42) is a variant of β-Amyloid (1-42) featuring the Dutch mutation (E22Q). This modified peptide demonstrates increased fibrillogenic and pathogenic characteristics, making it essential for studying amyloidogenesis and its implications in neurodegenerative diseases. Research applications include investigations into Alzheimer's disease mechanisms and the assessment of potential therapeutic interventions targeting amyloid aggregation. -
Stable Isotope
Protriptyline-d3 is a deuterated analog of the tricyclic antidepressant Protriptyline, serving as a stable isotope for research applications. It exerts potent inhibition of acetylcholinesterase (AChE) with an IC50 value of 0.06 mM and effectively inhibits amyloid beta (Aβ) self-assembly. This compound is valuable for studying the mechanisms underlying depression and Alzheimer's disease. -
Capsaicinoid Analog
Nordihydrocapsaicin is a capsacinoid analog known for its pungent properties and oral bioactivity. This compound exhibits potential anti-cancer activities and is derived from both fresh and processed peppers. It may induce a burning sensation upon consumption, making it relevant for research in pain mechanisms and anti-tumor effects. -
NF-κB Activator
Methylchloroisothiazolinone is a potent NF-κB activator known for its pro-inflammatory properties. It induces the expression of pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6, through the activation of the NF-κB signaling pathway and upregulation of TLR4. This compound is utilized in research focusing on allergic contact dermatitis and immunotoxicity mechanisms. Additionally, Methylchloroisothiazolinone demonstrates neurotoxic effects and has been shown to impair cholinesterase activity, leading to increased oxidative stress and detrimental impacts on aquatic organisms, specifically Mediterranean mussels. -
NF-κB Inhibitor
6-O-p-Hydroxybenzoylglutinoside is a selective NF-κB inhibitor that effectively suppresses TNF-α-activated NF-κB transcriptional activity, with an IC50 of 52.78 μM. This compound demonstrates targeted biological activity without significantly inhibiting soluble epoxide hydrolase (sEH), acetylcholinesterase (AChE), or butyrylcholinesterase (BChE). Isolated from the seeds of Catalpa bungei (Manchurian catalpa), 6-O-p-Hydroxybenzoylglutinoside is valuable for research applications focused on inflammation and signal transduction pathways. -
Anesthesia Agent
Desflurane is a volatile anesthetic agent that functions primarily by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA receptor, resulting in dose-dependent anesthesia. It is utilized in both surgical and diagnostic procedures requiring general anesthesia, offering rapid onset and recovery profiles. Additionally, desflurane is notable for its minimal metabolism, making it a valuable option in procedures requiring quick emergence from anesthesia. Its properties also make it suitable for studying the effects of anesthetics on neuronal activity.
